Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in Lung Cancer: A Systematic Review and Meta-Analysis

Xiang Shen, Hua Xiao, Shangke Huang, Jiexing Liu, Zhuolan Ran, Bin Xiong
doi: https://doi.org/10.1101/2020.01.08.20016915

ABSTRACT

Background Immune checkpoint inhibitors have brought hope for patients with advanced lung cancer, among which PD-1/PD-L1 and CTLA-4 inhibitors have achieved considerable results. This meta-analysis aims to investigate the efficacy and safety of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer.

Materials and Methods Randomized controlled trials (RCTs) study of PD-1/PD-L1 combined with CTLA-4 inhibitors for advanced lung cancer was searched in the database for systematic review and meta-analysis.

Results The meta-analysis finally included 4 trials (actually 3 trials), and the results showed that the overall response rate of PD-1/PD-L1 combined with CTLA-4 inhibitor was higher than that of the control group (ORR = 2.29 [95% CI 1.58 3.32], P <0.0001). PFS significantly improved compared with conventional treatment (HR = 0.69 [95% CI 0.56, 0.85], P = 0.0005), which was statistically significant. OS also improved but did not statistically significant (HR = 0.80 [95% CI 0.61, 1.05], P = 0.11). PD-1/PD-L1 combined with CTLA-4 inhibitors had a higher incidence of adverse reactions than conventional treatment (OR = 1.72 [95% CI 0.59, 5.09], P = 0.33), but the incidence of grade≥3 AEs was lower than the control group (OR = 0.96 [95% CI 0.64, 1.44], P = 0.85).

Conclusion Double checkpoint inhibitor PD-1/PD-L1 combined with CTLA-4 antibody has synergistic anti-cancer activity and improved ORR and PFS in lung cancer. Adverse reactions are more common than conventional treatment, but are generally controllable. Therefore, PD-1/PD-L1 combined with CTLA-4 inhibitors provides a beacon for the treatment of advanced lung cancer, which has guiding significance for the treatment selection in the future.

Introduction

Although undergoing smoking cessation, early screening and treatment have reduced lung cancer mortality,1 it still remains the most deadly cancer among cancer patients. Because lung cancer in the early stages is usually asymptomatic or has only cough and sputum without attention, most patients are diagnosed in the middle-late stages and haven’t opportunity for surgery. It analysised the 5-year survival rate of patients with stage IV is only 4% in the Cancer (2019).2 Even with the presence of treatable gene mutations, using targeted drugs will eventually activate acquired resistance mutations or compensatory pathways,3 leading to disease progression occurring 8-19 months after starting treatment.4,5 We need to actively find other therapies to solve this dilemma.

Studies have found that cancer cells in the context of the tumor microenvironment (TME) through regulatory T cells (Tregs) change immune homeostasis, suppress the activation and effector functions of innate and acquired immune systems, thereby escape immune surveillance.6,7 When PD-1 is combined with PD-L1, it inhibits the proliferation and survival of CD8 + toxic T cells;8 at the same time, changes T cell differentiation, impairs the differentiation of effector T cells (Teff) and memory T cells (Tm), up-regulates regulatory T lymphocytes (Treg) and depleted T cells (Tex), thus suppress T-cell immune effects. CTLA-4 has greater affinity than CD28 for binding to CD80 and CD86 on antigen-presenting cells, reducing the synergistic stimulation of the T cell receptor signal,9 thereby inhibiting CD28-B7-1/2 costimulation, leading to T cell dysfunction and apoptosis.10 This is the escape of adaptive immunity to endogenous anti-tumor mechanisms.11 Immune checkpoint inhibitors (ICIs) restore and maintain the function of the immune system against tumor cells by blocking specific signaling pathways, in which cytotoxic T cells play a important role in immune monitoring and anti-tumor responses.12 Compared with chemotherapy, PD-1/PD-L1 and CTLA-4 inhibitors have higher objective response rate or longer overall survival and better toxicity profile.13,14 In particular, patients without targeted cancer mutation genes receiving tumor immunotherapy is improved the long-term survival rate,15,16 and it is a new treatment standard for patients with advanced non-small cell lung cancer with new diagnosis, general conditions, and no contraindications.17

However, mono-immunotherapy significantly prolonged survival in patients with high PD-L1,18 which is only beneficial to a small number of patients.19 Greater therapeutic effectiveness can be achieved at the cost of corresponding side effects through synergistic or combined treatment. Recent clinical trials have demonstrated that the dual checkpoint inhibitors Ipilimumab plus Nivolumab can synergistically enhance T cell functions and the immune system’s ability to fight tumor cells through different and complementary mechanisms,20 have a better curative effect than Nivolumab monotherapy. The effect was better in patients with high PD-L1,21 and reducing the proportion of patients with advanced tumors.22

Immune-related adverse events (irAEs), which are different from chemotherapy-related toxic reactions,23 are up-regulated immune systems leading to severe inflammatory reactions and immune toxicity.24 The mechanism may be related to Tregs. Tregs are one of the most abundant suppressor cells in the TME, and express a large number of checkpoint molecules such as CTLA-4 and PD-1, to maintain immune homeostasis and avoiding autoimmunity. Therefore, the targeting effect of ICIs on Tregs may lead to the occurrence of irAEs.25 These events are usually controllable26 and can be effectively controlled and managed by immunosuppressive methods such as steroids.27 However, there are still a few patients happen serious adverse reactions, with the highest mortality caused by neurological and cardiac toxicity.28

Several clinical trials have been conducted to evaluate the efficacy and toxicity of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer, but the results such as progression-free survival (PFS) and overall survival(OS) are controversial. Therefore, we conducted a systematic meta-analysis using data from published literature to make a systematic review and meta-analysis on the efficacy and safety of PD-1/PD-L1 combined with CTLA-4 antibody and/or other therapeutic regiments in lung cancer.

Materials and methods

We follow principle in this systematic review and meta-analysis study is the system review and meta-analysis (PRISMA) guidelines for priority reporting projects.

Systematic Review and Meta-Analysis of All RCTs Testing the PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in lung cancer

Data sources and search strategy

We searched PubMed, Web of Science, the Cochrane Library, Ovid, Embase for RCTs testing the PD-1/PD-L1 plus CTLA-4 antibodies in patients with lung cancer, without any language or date restrictions. The following retrieval strategy was employed: ((((PD-1 OR PD-L1 OR Pembrolizumab OR Nivolumab OR Cemiplimab-rwlc OR Toripalimab OR Sintilimab OR Atezolizumab OR Avelumab OR Durvalumab) AND (CTLA-4 OR Ipilimumab OR Tremelimumab)) AND lung cancer) AND trial). And manual searches were performed for references that met the inclusion criteria to avoid missing any studies.

Inclusion and exclusion criteria

Inclusion and exclusion criteria were independently evaluated by two researchers based on the PICO principle. The included studies must meet the following criteria: (1) studies published in English; (2) randomized controlled clinical trials to study the efficacy and safety of (PD-1 OR PD-L1 OR Pembrolizumab OR Nivolumab OR Cemiplimab-rwlc OR Toripalimab OR Sintilimab OR Atezolizumab OR Avelumab OR Durvalumab) AND (CTLA-4 OR Ipilimumab OR Tremelimumab); (3) the patients were histologically diagnosed with lung cancer,not including HIV, organ transplantation, viral infection and other special patients; (4) analysis related data of objective response rate(ORR), progression free survival (PFS), overall survival (OS), and toxicity. The following studies were excluded: (1) reviews, editorials, case reports, or animal and cellular studies; (2) incomplete required data; (3) no dose and usage.

Data extraction and quality assessment

Two researchers independently conducted the study selection process based on the inclusion and exclusion criteria, and extracted the following information: first author name, publication year, trial phase, clinical trial number, trial design, pathological type, sample size, usage and dosage, follow-up time, median OS and PFS, irAEs. If there are disagreements in the studies selection and data extraction process, reach a consensus through discussion or when necessary consult the third investigator.

We used the reporting method of Jadad et al29 to evaluate the quality of the included studies.

Data synthesis and statistical analysis

We used Review Manager 5.3 for statistical analysis. The Q test and I2 statistics were evaluated the statistical heterogeneity. When P<0.05 or I2>50%, heterogeneity is indicated statistically significant, and performed using random effects models, otherwise performed using fixed effect model. HRs>1 of OS and PFS was beneficial to the control group, while HRs<1 was beneficial to the PD-1/PD-L1 combined CTLA-4 antibody group. ORs>1 of ORR and AEs means higher effective rate and toxicity, while ORs<1 have lower effective rate and safety. P<0.05 was considered statistically significant, and all P values were bilateral.

Results

Study characteristics and risk of bias

Figure 1 shows a flow chart containing the study. A preliminary literature search screened a total of 3983 records from the database; 3317 of them were after deleting duplicate records; 86 were after screening; 43 were after screening titles and abstracts; 3 studies After reviewing each publication. All relevant references have been reviewed. Finally, three randomized controlled trials were included in this meta-analysis (one of the trials had two trials to compare the efficacy and toxicity with the control group, which were conducted as two independent trials), all using the response evaluation standard (RECIST) or WHO standards. All trials are randomized, controlled, open-label clinical trials. These included 430 experimental groups and 375control groups,30-32 which mainly studied Ipilimumab + Nivolumab and Durvalumab + Tremelimumab for the treatment of lung cancer. Table I summarizes the detailed characteristics of the included studies.

Figure

We assessed the quality of each study in this analysis based on the Jadad score, and Table II provides the risk results of the bias assessment.

View this table:
Table II

Risk of Bias

Overall response rate (ORR)

Finally, 4 studies conducted in 430 experimental arm patients and 375 control arm patients met the inclusion criteria and were included in the ORR analysis. The ORR funnel plot did not show significant asymmetry (Figure 3), and heterogeneity between studies was not significant (P= 0.99, I2=0%). The pooled OR for ORR was performed fixed effect model. This meta-analysis showed that ORR was significantly improved in the treatment of PD-1/PD-L1 combined with CTLA-4 antibody (OR=2.29[95%CI 1.58, 3.32], P<0.0001) (Figure 2), which was statistically significant. The clinical efficacy of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer is higher than that in the control group. Regardless of whether it is NSCLC or SCLC, the results show that dual ICI therapies improves ORR.

Figure
Figure

progression-free survival (PFS)

Two trials were included for PFS evaluation. The funnel plot of PFS did not show significant asymmetry, and heterogeneity among studies was not significant (P = 0.19, I2 = 42%). The pooled HR for PFS was performed fixed effect model. In the treatment of lung cancer with PD-1/PD-L1 combined with CTLA-4 antibodies, the HR of PFS improved statistically (HR = 0.69 [95% CI 0.56, 0.85], P = 0.0005) (Figure 4).

Figure

overall survival (OS)

Only one trial reported OS combined HRs and 95% CI, and heterogeneity could not be evaluated. The results showed that the OS of PD-1/ PD-L1 combined with CTLA-4 antibody was improved but not statistically significant (HR = 0.80[95% CI 0.61, 1.05], P = 0.11) (Figure 5).

Figure

Immune-related adverse events (irAEs)

Data from AEs were found in 3 studies with significant heterogeneity (P = 0.0002, I2 = 89%). The pooled OR for AEs was performed random effect model. The incidence of AEs was higher than the control group (OR = 1.72 [95% CI 0.59, 5.09], P = 0.33) (Figure 6), and fatigue was the most common. There are 4 studies with data from severe AEs (Grade ≥ 3) and heterogeneity (P = 0.1, I2 = 52%). The pooled OR for AEs (Grade≥3) was performed random effect model. The incidence of AEs (Grade ≥ 3) was lower than the control group (OR = 0.96[95%CI 0.64, 1.44], P = 0.85) (Figure 7), but it was not obvious. Among them, rash and diarrhea were the most common, anemia and neutrophilic granulocyte counts were most common during chemotherapy.

Figure

Discussion

Most lung caner patients receive chemotherapy and/or radiation therapy,2 which have poor antitumor effects. In recent years, some clinical trials have achieved satisfactory results in the treatment of lung cancer with PD-1/PD-L1 and CTLA-4 antibodies, of which Pembrolizumab and Nivolumab can prolong survival for patients with advanced NSCLC,33,34 Durvalumab combined with chemotherapy can effectively improve the prognosis of patients with ES-SCLC.35 This meta-analysis investigates the efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors for lung patients.

Nivolumab and Pembrolizumab mainly act on activated T cells in peripheral blood or tumors. By blocking the binding of PD-1 and PD-L1, they cancell the apoptosis of T cells and enable their normal activation and proliferation. Ipilimumab mainly acts on lymph nodes, by blocking the binding of the domain of CTLA-4 to its ligand, activate, proliferate and infiltrate T lymphocytes, and increase the level of active T cells in peripheral blood.36 However, less than 10% of CD8+ T cells in tumors have the ability to recognize cancer cells,37 and the anticancer effect may be caused by T cells entering the tumor from peripheral blood after treatment.38 Therefore, it is particularly important to increase the number of T cells and enhance the effector function through different mechanisms by combining PD-1/PD-L1 and CTLA-4 inhibitors. The combined blocking of CTLA-4 and PD-1/PD-L1 pathways increases the ratio of Teff to Tregs and myeloid-derived suppressor cells (MDSC, which significantly suppresses the ability of cells to respond), thereby reducing immunosuppression and promoting inflammation in the tumor microenvironment.39 At the same time, anti-CTLA-4 antibodies have antibody-dependent cell-mediated cytotoxicity, reduce the negative effect of PD-1 antibodies on activating Tregs; CTLA-4 antibodies lead to compensatory overexpression of tumor PD-L1, and PD-1 antibodies block the binding of PD-L1 to PD-1; CTLA-4 antibodies increase activated T cells and Tm in peripheral blood, and PD-1 antibodies relieve the inhibition of T cell anti-cancer activity by tumors. Our results reveal the significant effect of dual checkpoint inhibitors treat for advanced lung cancer, with significant improvements in ORR (OR=2.29[95%CI 1.58, 3.32], P<0.0001) and PFS (HR = 0.69 [95% CI 0.56, 0.85], P = 0.0005); OS also improves (HR = 0.80[95% CI 0.61, 1.05], P = 0.11), but no statistical significance.

Can we combine immunosuppressants with other treatments for lung cancer? By activating aKT, cisplatin rapidly increases the expression of PD-L1 in the tumor microenvironment in a dose-dependent manner, increases the clinical efficacy of immunotherapy,40,41 and does not affect the immune background of NSCLC after induction, and does not significantly damage antitumor Immune,42 but may not persistently. Radiotherapy can restore the recruitment of Th1 lymphocytes in the tumor microenvironment,43 stimulate antigen presentation, increase tumor antigenicity,44 form an “immune center”, promote tumor immune response.45,46 Through more effective control of the immune system, local therapy is converted into systemic therapy, which makes it have synergistic and more effective activity on tumor cells.47 Regarding when to use combination therapy, a meta-analysis by Zhou et.al suggests patients with large tumor volume should be treated with immunity combined with other therapies to produce deeper and long-term efficacy, while patients with low tumor volume or extremely high PD-L1 TPS should be treated with immunomonotherapy.48 which requires more clinical trials validation.

In order to expand the population benefiting from immunotherapy, detection of biomarkers before treatment is necessary. In the Checkmate 568 study, patients with stage IIIB/IV NSCLC received Nevolumab and Ipilimumab. The ORs of patients with PD-L1 expression < 1% and ≥ 1% were 14.9%[95% CI 8.9, 22.8], 41.3%[95% CI 33,50], respectively, MPFS is 2.8months[95% CI 2.1,4.0], 6.8months[95% CI 4.0, 11.3], and the OR of patients with PD-L1 ≥ 50% is 50%[95% CI 37.6, 62.4].49 It is suggested that tumor PD-L1 expression is significantly enhanced when receiving dual immunosuppressants at 1% or higher, which has been considered to a predictive biomarker of immune checkpoint inhibitor response.50 However, PD-L1 expression is heterogeneous and is affected by chemotherapy and targeted therapy.51 The immune response to anti-CTLA-4 or anti-PD-1/CTLA-4 combination therapy in high TMB tumors may not depend on PD-L1 expression.52 Several studies have shown a correlation between TMB and the benefits of ICIs in NSCLC, SCLC, and melanoma.53 The higher the TMB, the more mutations in the tumor genome, the higher the probability of new antigens appearing on the tumor surface, the stronger the immunogenicity, making the tumor more easily recognized by T cells;54 and it is significantly related to the response of immunotherapy.55 Hellmann et al. according to TMB quantitative classification: low (0 to <143 mutations), medium (143 to 247 mutations) and high (≥248 mutations), the ORR of Nivolumab+ipilimumab in SCLC is 22.2%, 16.0%, 46.2%, MPFS is 1.5 months[95% CI 1.3, 2.7], 1.3 months[95% CI 1.2, 2.1], 7.8 months[95%CI 1.8, 10.7], MOS is 3.4 months[95% CI 2.8,7.3], 3.6 months[95% CI 1.8,7.7], 22.0 months[95% CI 8.2, NR], suggesting that dual immunosuppressants have better therapeutic effect and larger clinical value in patients with high tumor mutation load.56 The expression of PD-L1 and TMB can be used as predictors of immunotherapy.

The related adverse reactions of PD-1/PD-L1 combined with CTLA-4 inhibitors cannot be ignored. The risk of irAEs in patients treated with CTLA-4 is dose-related,57 most grade 3 or higher irAES occurs within 8-12 weeks after starting treatment; PD-1 antibody-related irAEs are relatively low in frequency, most irAEs occur within the first 6 months of treatment and take longer than treatment of CTLA-4 related toxicity.58 The organ involvement spectrum of the two is also different, anti-PD-1 drugs cause arthritis more frequently, and anti-CTLA-4 drugs are more related to colitis.59 Combining anti-CTLA-4 antibodies and anti-PD-1 antibodies can increase the incidence and severity of irAEs and occur earlier.60 This is consistent with our research finding. A big data analysis showed that the risk of immune events is associated with TMB. Cancers with high TMB, such as NSCLC, are associated with higher irAEs during anti-PD-1 therapy.61 Receiving low-dose glucocorticoids does not inhibit the immune response caused by ICIS, and can continue and maintain a beneficial response to ICIs.59 The combination of anti-PD-1 antibodies and immune antibodies of selectively target specific inflammatory mediators can prevent or delay the progression of advanced tumors with autoimmune diseases without affecting the anti-tumor effect of anti-PD-1 antibodies.62 It was observed that even if patients receiving PD-1 antibodies stopped treatment due to the reaction, they could have a longer duration of action without the need to rush to the next treatment.63 However, long-term exposure to immunosuppressants can lead to rare fatal immune-related events.64,65

In our meta-analysis, we included 4 randomized controlled clinical trials, the results showed that the combination of PD-1/PD-L1 and CTLA-4 antibody was effective for the treatment of lung cancer and the occurrence of adverse reactions is controllable.It provides a good option for the treatment of SCLC. A non-randomized controlled trial of Ipilimumab and Nivolumab given postoperatively to patients with ES-SCLC was better than the control group compared with OS-1 year.66 Contrary to our findings, more randomized, multicenter, and large sample studies are needed to confirm and evaluate the cost of treatment strategies and patients’ quality of life. Our research also has certain limitations that may affect the final results. First, most studies have a small sample size, and currently there are very few data on dual-immune checkpoint inhibitor combination therapy, and fewer studies involving randomized or blinded methods. Second, we extracted trial data from published articles but did not have the patient’s original data, which could lead to biases in data analysis. Therefore, more large-scale clinical trials are needed to further verify the effectiveness and safety of dual immunosuppressive antitumor therapy. Multiple RCTs are currently underway to compare the efficacy of PD-1/PD-L1 in combination with CTLA-4 inhibitors and/or other treatment options for advanced cancer, Durvalumab + Tremelimumab (MYSTIC/NCT02453282,67 ADRIATIC/NCT03703297,68 NEPTUNE/NCT0254229369), Durvalumab + Tremelimumab + Chemotherapy (POSEIDON/NCT03164616,70 CASPIAN/NCT0304387271), Nivolumab + Ipilimumab (CheckMate227/NCT02477826,72 CheckMate816/NCT0299852873), Pembrolizumab + Ipilimumab (KEYNOTE-598/NCT0330223474). It is necessary to pay close attention to the test results, perform update analysis, and conduct long-term follow-up.

In conclusion, PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors can improve ORR and PFS in patients with advanced or metastatic lung cancer, but the incidence of adverse reactions is high and generally tolerable. The survival of SCLC is shorter than that of NSCLC,2 and treatment is limited. Dual immunosuppressants also have therapeutic effects in SCLC. Despite some limitations, our research indicates that the current PD-1/PD-L1 plus CTLA-4 inhibitors may be a promising treatment strategy for patients with advanced lung cancer, but attention should be paid to the occurrence of adverse reactions.

Data Availability

No data are available.

Footnotes

Contributors

XS and HX: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval; JL and ZR: acquisition of data, analysis and interpretation of data, drafting the article, final approval; SH: interpretation of data, revising the article, final approval; BX: interpretation of data, revising the article, critical revision,final approval.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

No data are available.

REFERENCE

  1. 1.↵
    Jiemin M, Ahmedin J, Stacey AF, et al. The American Cancer Society 2035 challenge goal on cancer mortality reduction. CA Cancer J Clin 2019;69:351–62 doi:10.3322/caac.21564 [Published Online First: 08 May 2019].
    OpenUrlCrossRef
  2. 2.↵
    Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363–85 doi:10.3322/caac.21565 [Published Online First: 11 June 2019].
    OpenUrlCrossRefPubMed
  3. 3.↵
    Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res 2019;7:1457–71 doi:10.1158/2326-6066.cir-18-0595.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol Published Online First: 16 Jan 2018 doi:10.2217/fon-2017-0636.
    OpenUrlCrossRef
  5. 5.↵
    Morris TA, Khoo C, Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. Drugs 2019;79:1277–86 doi:10.1007/s40265-019-01164-3 [Published Online First: 16 July 2019].
    OpenUrlCrossRef
  6. 6.↵
    Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review. J Cell Physiol 2019;234:7983–7993 doi:10.1002/jcp.27553 [Published Online First: 14 Oct 2018].
    OpenUrlCrossRef
  7. 7.↵
    Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015;35(Suppl):S185–98 doi:10.1016/j.semcancer.2015.03.004.
    OpenUrlCrossRef
  8. 8.↵
    Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69–74 doi:10.1126/science.aaa4971 [Published Online First: 03 Apr 2015].
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Barber D.L, Wherry E.J, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682–7 doi:10.1038/nature04444 [Published Online First: 28 Dec 2015].
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61 doi:10.1016/j.ccell.2015.03.001.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Paulsen EE, Kilvaer TK, Rakaee M, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother 2017;66:1449–61 doi:10.1007/s00262-017-2039-2.
    OpenUrlCrossRef
  12. 12.↵
    Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med 2019;51:94 doi:10.1038/s12276-019-0295-2 [Published Online First:09 August 2019].
    OpenUrlCrossRef
  13. 13.↵
    Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial. Lancet 2017;389:255–65 doi:10.1016/s0140-6736(16)32517-x [Published Online First:12 Dec 2016].
    OpenUrlCrossRefPubMed
  14. 14.↵
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50 doi:10.1016/s0140-6736(15)01281-7 [Published Online First: 19 Dec 2015].
    OpenUrlCrossRefPubMed
  15. 15.↵
    Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 30:863–70 doi:10.1093/annonc/mdy474.
    OpenUrlCrossRef
  16. 16.↵
    Schuler M, Paz-Ares L, Sequist LV, et al. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer 2019;133:10–19 doi:10.1016/j.lungcan.2019.04.006.
    OpenUrlCrossRef
  17. 17.↵
    Ackermann CJ, Reck M, Paz-Ares L, et al. First-line immune checkpoint blockade for advanced Non-Small-Cell Lung Cancer: travelling at the speed of light. Lung Cancer 2019;134:245–53 doi:10.1016/j.lungcan.2019.06.007
    OpenUrlCrossRefPubMed
  18. 18.↵
    Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out. Cancer Treat Rev 2019;75:39–51 doi:10.1016/j.ctrv.2019.03.004
    OpenUrlCrossRefPubMed
  19. 19.↵
    Verma V, Sharma G, Singh A. Immunotherapy in extensive small cell lung cancer. Exp Hematol Oncol 2019;8:5 doi:10.1186/s40164-019-0129-x [Published Online First: 04 Fed 2019].
    OpenUrlCrossRef
  20. 20.↵
    Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol 2018;29(uppl 10):abstract LBA6.
  21. 21.↵
    Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31–41 doi:10.1016/S1470-2045(16)30624-6 [Published Online First: 05 Dec 2016].
    OpenUrlCrossRefPubMed
  22. 22.↵
    Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:1270–1 doi:10.1056/nejmc1509660 [Published Online First: 24 Sep 2015].
    OpenUrlCrossRef
  23. 23.↵
    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–68 doi:10.1056/nejmra1703481 [Published Online First: 11 Jan 2018].
    OpenUrlCrossRefPubMed
  24. 24.↵
    Naqash AR, Appah E,Yang LV, et al. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 2019;7:169 doi:10.1186/s40425-019-0648-3 [Published Online First: 05 July 2019].
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    Alissafi T, Hatzioannou A, Legaki AI, et al. Balancing cancer immunotherapy and immune-related adverse events: The emerging role ofregulatory T cells. J Autoimmun 2019;104:102310 doi:10.1016/j.jaut.2019.102310
    OpenUrlCrossRef
  26. 26.↵
    Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther 2017;6:51–71 doi: 10.2147/itt.s141577 [Published Online First:24 Aug 2017]
    OpenUrlCrossRef
  27. 27.↵
    Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36:1714–68 doi:10.1200/jco.2017.77.6385 [Published Online First:14 Feb 2018].
    OpenUrlCrossRefPubMed
  28. 28.↵
    Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016;27:559–74 doi:10.1093/annonc/mdv623
    OpenUrlCrossRefPubMed
  29. 29.↵
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Kowalski DM, Reinmuth N, Orlov SV, et al. ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment. Ann Oncol 2018;29(suppl 8):abstract 1378O.
  31. 31.
    Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018, 378:2093–04 doi:10.1056/nejmoa1801946 [Published Online First:31 May 2018].
    OpenUrlCrossRefPubMed
  32. 32.↵
    Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–95 doi:10.1016/S1470-2045(16)30098-5 [Published Online First:04 June 2016].
    OpenUrlCrossRefPubMed
  33. 33.↵
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–1550 doi:10.1016/S0140-6736(15)01281-7 [Published Online First:19 Dec 2015].
    OpenUrlCrossRefPubMed
  34. 34.↵
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627–1639 doi:10.1056/NEJMoa1507643 [Published Online First:22 Oct 2015].
    OpenUrlCrossRefPubMed
  35. 35.↵
    Paz-Ares L, Dvorkin M, Chen YB, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929–39 doi:10.1016/S0140-6736(19)32222-6 [Published Online First:23 Nov 2019].
    OpenUrlCrossRefPubMed
  36. 36.↵
    Robert L, Tsoi J, Wang X, et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clin Cancer Res 2014;20: 2424–32 doi:10.1158/1078-0432.ccr-13-2648
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med 2018;25:89–94 doi:10.1038/s41591-018-0266-5 [Published Online First:03 Dec 2018].
    OpenUrlCrossRef
  38. 38.↵
    Li JY, Byrne KT, Yan FX, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 2018;49:178–193.e7 doi:10.1016/j.immuni.2018.06.006 [Published Online First:26 June 2018].
    OpenUrlCrossRefPubMed
  39. 39.↵
    Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:39 doi: 10.1186/s40425-018-0349-3.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    Tran L, Allen CT, Xiao R, et al. Cisplatin Alters Antitumor Immunity and Synergizes with PD1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res 2017;5:1141–51 doi:10.1158/2326-6066.CIR-17-0235
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett 2019;464:5–14 doi:10.1016/j.canlet.2019.08.005
    OpenUrlCrossRef
  42. 42.↵
    Remark R, Lupo A, Alifano M, et al. Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. Oncoimmunology 2016;5:e1255394 doi:10.1080/2162402X.2016.1255394 [Published Online First:18 Dec 2016].
    OpenUrlCrossRef
  43. 43.↵
    Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 2013;19:565–82 doi:10.1016/j.molmed.2013.05.007 [Published Online First:09 July 2013].
    OpenUrlCrossRefPubMed
  44. 44.↵
    Bos PD, Plitas G, Rudra D, et al. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 2013;210:2435–66 doi:10.1084/jem.20130762 [Published Online First:14 Oct 2013].
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012;189:558–66. doi:10.4049/jimmunol.1200563 [Published Online First:15 July 2012]
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    Demaria S, Bhardwaj N, McBride W.H, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655–66 doi: 10.1016/j.ijrobp.2005.06.032 [Published Online First:01 Nov 2005]
    OpenUrlCrossRefPubMed
  47. 47.↵
    De WK, Vermaelen K, De MG, et al. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology 2015;4:e1042198 doi: 10.1080/2162402X.2015.1042198 [Published Online First:27 May 2015].
    OpenUrlCrossRef
  48. 48.↵
    Buttigliero C, Allis S, Tucci M, et al. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treat Rev 2018, 69:215–23 doi:10.1016/j.ctrv.2018.07.010
    OpenUrlCrossRef
  49. 49.↵
    Ready N, Hellmann MD, Awad MM, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol 2019;37:992–1000 doi:10.1200/JCO.18.01042 [Published Online First:20 Feb 2019].
    OpenUrlCrossRef
  50. 50.↵
    Yu H, Boyle TA, Zhou C, et al. PD-L1 Expression in Lung Cancer. J Thorac Oncol 2016;11:964–975 doi:10.1016/j.jtho.2016.04.014
    OpenUrlCrossRef
  51. 51.↵
    Chan TA, Yarchoan M, Jaffee E, et al. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Ann Oncol 2018;30:44–56 doi:10.1093/annonc/mdy495 [Published Online First:05 Nov 2018].
    OpenUrlCrossRef
  52. 52.↵
    Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2016;165:35–44 doi:10.1016/j.cell.2016.02.065 [Published Online First:24 Mar 2016].
    OpenUrlCrossRefPubMed
  53. 53.↵
    Hellmann MD, Nathanson T, Rizvi H, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 2018;33:843-852.e4 doi:10.1016/j.ccell.2018.03.018 [Published Online First:12 Apr 2018].
    OpenUrlCrossRefPubMed
  54. 54.↵
    Riaz N, Morris L, Havel JJ, et al. The role of neoantigens in response to immune checkpoint blockade. Int Immunol 2016;28:411–9 doi:10.1093/intimm/dxw019.
    OpenUrlCrossRefPubMed
  55. 55.↵
    Forschner A, Battke F, Hadaschik D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. J Immunother Cancer 2019;7:180 doi:10.1186/s40425-019-0659-0 [Published Online First: 12 July 2019].
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    Hellmann MD, Margaret KC, Mark MA, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2018;33:853 doi:10.1016/j.ccell.2018.04.001 [Published Online First:14 May 2018].
    OpenUrlCrossRefPubMed
  57. 57.↵
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375:1845–55 : doi:10.1056/NEJMoa1611299 [Published Online First:10 Nov 2016].
    OpenUrlCrossRefPubMed
  58. 58.↵
    Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors:epidemiology,management and surveillance. Nat Rev Clin Oncol 2019;16:563–80 doi:10.1038/s41571-019-0218-0 [Published Online First:15 May 2019].
    OpenUrlCrossRefPubMed
  59. 59.↵
    Buckley LM, Suarez-Almazor ME. Is Immune Check Point Inhibitor Treatment an Option for Patients with Rheumatic Diseases and Cancer? Arthritis Rheumatol 2019;71:1971–73 doi:10.1002/art.41064
    OpenUrlCrossRef
  60. 60.↵
    Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–17 doi: 10.1056/NEJMoa1414428 [Published Online First:]
    OpenUrlCrossRefPubMed
  61. 61.↵
    Bomze D, Hasan Ali O, Bate A, et al. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. JAMA Oncol 2019;5:1633–1635 doi:10.1001/jamaoncol.2019.3221 22 [Published Online First:Aug 2019].
    OpenUrlCrossRef
  62. 62.↵
    Uemura M, Trinh VA, Haymaker C, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. J Hematol Oncol 2016;9:81 doi:10.1186/s13045-016-0309-7
    OpenUrlCrossRefPubMed
  63. 63.↵
    Iivanainen S, Koivunen JP. Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. Oncology Published Online First:31 Oct 2018 doi: 10.1159/000493193.
    OpenUrlCrossRef
  64. 64.↵
    Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:1721–8 doi:10.1001/jamaoncol.2018.3923 [Published Online First:13 Sep 2018]
    OpenUrlCrossRefPubMed
  65. 65.↵
    Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 2018;29(uppl 4): iv264–iv266 doi:10.1093/annonc/mdy162.
    OpenUrlCrossRefPubMed
  66. 66.↵
    Perez BA, Kim S, Dilling TJ, et al. A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung. Int J Radiat Oncol Biol Phys 2019;105: S36 doi:10.1016/j.ijrobp.2019.06.452 [Published Online First:1 sep 2019].
    OpenUrlCrossRef
  67. 67.↵
    Von Pawel J, Fischer J, Alt J, et al. MYSTIC - A Phase III, randomized, open-label study of Durvalumab (MEDI4736) in combination with Tremelimumab or Durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced stage IV non small cell lung cancer (aNSCLC): A German update. Oncol Res Treat 2016;39:87.
    OpenUrl
  68. 68.↵
    Senan S, Shire N, Mak G, et al. ADRIATIC: A phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer. Ann Oncol 2019;30:25.
    OpenUrl
  69. 69.↵
    Mok T, Schmid P, De Castro G, et al. First-line durvalumab plus tremelimumab vs platinum-based chemotherapy for advanced/metastatic NSCLC: Phase 3 NEPTUNE Study. J Thorac Oncol 2017;12:S1084.
    OpenUrl
  70. 70.↵
    Thomas M, Grohe C, Eberhardt W, et al. POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab + chemotherapy vs chemotherapy alone in metastatic NSCLC. Oncol Res Treat 2018;41:295.
    OpenUrl
  71. 71.↵
    Paz-Ares L, Jiang H, Huang Y, et al. Caspian: Phase 3 study of first-line durvalumab ± tremelimumab + platinum-based chemotherapy vs chemotherapy alone in ED-SCLC. J Thorac Oncol 2017;12:S2398.
    OpenUrl
  72. 72.↵
    Paz-Ares L, Brahmer J, Hellmann MD. CheckMate 227: A randomized, open-label phase 3 trial of nivolumab nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017;28.
  73. 73.↵
    Felip E, Brahmer J, Broderick S, et al. CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC. J Thorac Oncol 2018;13:S831–S832 doi:10.1016/j.jtho.2018.08.1478
    OpenUrlCrossRef
  74. 74.↵
    Boyer M, McLean J, Xu L, et al. Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598. J Thorac Oncol 2018;13:S462 doi:10.1016/j.jtho.2018.08.565.
    OpenUrlCrossRef
Back to top
Posted January 10, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in Lung Cancer: A Systematic Review and Meta-Analysis
Xiang Shen, Hua Xiao, Shangke Huang, Jiexing Liu, Zhuolan Ran, Bin Xiong
medRxiv 2020.01.08.20016915; doi: https://doi.org/10.1101/2020.01.08.20016915
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area